<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766892</url>
  </required_header>
  <id_info>
    <org_study_id>MYK-461-019</org_study_id>
    <nct_id>NCT04766892</nct_id>
  </id_info>
  <brief_title>A Study of Mavacamten in Participants With HFpEF and Chronic Elevation of cTnI and/or NT-proBNP</brief_title>
  <acronym>EMBARK-HFpEF</acronym>
  <official_title>An Exploratory, Open-label, Proof-of-concept, Phase 2a Study of Mavacamten (MYK-461) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Chronic Elevation of Cardiac Troponin I and/or NT-proBNP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MyoKardia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MyoKardia, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a proof-of-concept study to assess safety, tolerability, and preliminary&#xD;
      efficacy of mavacamten treatment on biomarkers levels in participants with heart failure with&#xD;
      preserved ejection fraction (HFpEF) and chronic elevation of cTnI and/or NT-proBNP. Data from&#xD;
      this study will inform future study designs of mavacamten in participants with HFpEF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of treatment-emergent adverse events, adverse events of special interest, and serious adverse events.</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mavacamten effect on cTnI levels (at rest)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Specifically, change from baseline to Week 26 in cTnI (resting), as assessed by a high-sensitivity assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mavacamten effect on NT-proBNP levels (at rest)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Specifically, change from baseline to Week 26 in NT-proBNP (resting)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Mavacamten (MYK-461)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mavacamten</intervention_name>
    <description>Mavacamten Capsules</description>
    <arm_group_label>Mavacamten (MYK-461)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Is at least 50 years old at Screening.&#xD;
&#xD;
          2. Body weight is greater than 45 kg at Screening.&#xD;
&#xD;
          3. Documented prior objective evidence of heart failure as shown by 1 or more of the&#xD;
             following criteria:&#xD;
&#xD;
               -  Previous hospitalization for heart failure with documented radiographic evidence&#xD;
                  of pulmonary congestion.&#xD;
&#xD;
               -  Elevated LV end-diastolic pressure or pulmonary capillary wedge pressure at rest&#xD;
                  (≥15 mm Hg) or with exercise (≥25 mm Hg).&#xD;
&#xD;
               -  Elevated level of NT-proBNP (&gt;400 pg/mL) or brain natriuretic peptide (BNP) (&gt;200&#xD;
                  pg/mL).&#xD;
&#xD;
               -  Echocardiographic evidence of medial E/e' ratio ≥ 15 or left atrial enlargement&#xD;
                  (left atrial volume index &gt;34 mL/m2) together with chronic treatment with&#xD;
                  spironolactone, eplerenone, or a loop diuretic.&#xD;
&#xD;
          4. Meets 1 or more of the following criteria:&#xD;
&#xD;
               -  A hs-cTnI &gt;99th percentile at screening OR&#xD;
&#xD;
               -  NT-proBNP* &gt;300 pg/mL at initial screening measurement (if not in atrial&#xD;
                  fibrillation or atrial flutter) or &gt;750 pg/mL (if in atrial fibrillation or&#xD;
                  atrial flutter). OR&#xD;
&#xD;
               -  If the screened participant is either of African descent or has a body mass index&#xD;
                  ≥30.0 kg/m2, a screening NT-proBNP* &gt;240 pg/mL (if not in atrial fibrillation or&#xD;
                  atrial flutter) or &gt;600 pg/mL (if in atrial fibrillation or atrial flutter).&#xD;
&#xD;
          5. Has documented LVEF ≥60% at the Screening visit and no history of prior LVEF ≤ 45%&#xD;
&#xD;
          6. Has documented elevated left ventricular mass index (LVMI) by 2-dimensional imaging&#xD;
             (&gt;95 g/m2 if female and &gt;115 g/m2 if male) OR maximal left ventricular wall thickness&#xD;
             ≥12 mm.&#xD;
&#xD;
          7. Has adequate acoustic windows on screening resting TTE&#xD;
&#xD;
          8. Has NYHA class II or III symptoms at Screening.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Has a prior diagnosis of HCM OR a known infiltrative or storage disorder causing HFpEF&#xD;
             and/or cardiac hypertrophy, such as amyloidosis, Fabry disease, or Noonan syndrome&#xD;
             with LV hypertrophy OR a positive serum immunofixation result.&#xD;
&#xD;
          2. Has a history of syncope within the last 6 months or sustained ventricular tachycardia&#xD;
             with exercise within the past 6 months.&#xD;
&#xD;
          3. Has a history of resuscitated sudden cardiac arrest at any time or known appropriate&#xD;
             implantable cardioverter defibrillator discharge within 6 months prior to Screening.&#xD;
&#xD;
          4. Has persistent or permanent atrial fibrillation not on anticoagulation for at least 4&#xD;
             weeks prior to Screening and/or is not adequately rate controlled within 6 months&#xD;
             prior to Screening.&#xD;
&#xD;
          5. Currently treated or planned treatment during the study with either: (a) a combination&#xD;
             of beta blocker and verapamil or a combination of beta blocker and diltiazem, (b)&#xD;
             disopyramide, or (c) biotin or biotin-containing supplements/multivitamins.&#xD;
&#xD;
          6. Has known moderate or severe aortic valve stenosis, hemodynamically significant mitral&#xD;
             stenosis, or severe mitral or tricuspid regurgitation at Screening&#xD;
&#xD;
          7. Has severe chronic obstructive pulmonary disease, or other severe pulmonary disease,&#xD;
             requiring home oxygen, chronic nebulizer therapy, chronic oral steroid therapy or&#xD;
             hospitalized for pulmonary decompensation within 12 months.&#xD;
&#xD;
          8. Has body mass index ≥45.0 kg/m2&#xD;
&#xD;
          9. Has left ventricular global longitudinal strain by TTE in the range from 0 to -12.0&#xD;
             (assessed by central TTE reader)&#xD;
&#xD;
         10. Has NT-proBNP at Screening &gt;2000 pg/mL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BMS Medical Information Team</last_name>
    <phone>(Use email contact)</phone>
    <email>clinical.trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Myokardia Medical Information Team Study Director</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Florian Rader, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Koren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infinite Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Melvin Martinez-Castrillon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ravi Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana Heart Center</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruce Iteld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Fermin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Parag Goyal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ravi Karra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Lindner Center for Research and Education at the Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Timothy Raymond, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Oklahoma Heart Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Naeem Tahirkheli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sophia Airhart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ahmad Masri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania - Heart and Vascular Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anjali Owens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sheldon Litwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stern Cardiovascular Foundation, Inc</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Jeffries, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital &amp; Clinics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Omar Wever-Pinzon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HFpEF</keyword>
  <keyword>Cardiac troponin I</keyword>
  <keyword>NT-proBNP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

